Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Tentative FDA approval for generic analgesic

Oct. 18, 1996

Merck & Co. reveals new series of tachykinin antagonists

Oct. 18, 1996

Yamanouchi's CNS products in the pipeline

Oct. 11, 1996

Novel treatment for chronic fatigue syndrome available in Canada

Oct. 11, 1996

Novel free radical-scavenging and neuroprotective substance isolated by Japanese researchers

Oct. 11, 1996

Calpain inhibitors reported by Warner-Lambert

Oct. 11, 1996

New muscarinic antagonists from Schering-Plough

Oct. 11, 1996

Copaxone approvable for MS

Oct. 11, 1996

FDA approval for Taro generic drug

Oct. 11, 1996

First launch for olanzapine

Oct. 11, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...